Cancer of the ovary.

Patients with ovarian cancer usually present with advanced disease, and the disease is generally managed with surgical resection followed by platinum-based chemotherapy. Recent chemotherapeutic advances have led to improved survival, and a better understanding of genetic risk factors has permitted a tailored approach to preventive strategies, such as bilateral salpingo-oophorectomy in selected women. This review describes the clinical features of ovarian cancer and recent advances in postoperative management.

[1]  A. Manetta,et al.  Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. , 1997, Gynecologic oncology.

[2]  V. Torri,et al.  Controversial issues in the management of early epithelial ovarian cancer: conservative surgery and role of adjuvant therapy. , 1994, Gynecologic oncology.

[3]  A. Whittemore.  Characteristics relating to ovarian cancer risk: implications for prevention and detection. , 1994, Gynecologic oncology.

[4]  S. Self,et al.  Ovarian tumors in a cohort of infertile women. , 1994, The New England journal of medicine.

[5]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[6]  R. Barakat,et al.  Epithelial ovarian cancer in the elderly: The memorial sloan‐kettering cancer center experience , 2010 .

[7]  W. Willett,et al.  Tubal Ligation, Hysterectomy, and Risk of Ovarian Cancer: A Prospective Study , 1993 .

[8]  J. Niloff,et al.  Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Piver,et al.  Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the gilda radner familial ovarian cancer registry , 1993, Cancer.

[10]  T. Tong,et al.  Cancer statistics, 1993 , 1993, CA: a cancer journal for clinicians.

[11]  R. Berkowitz,et al.  The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. , 1992, Gynecologic oncology.

[12]  E. Petru,et al.  Nongenital cancers metastatic to the ovary , 1992, Gynecologic oncology.

[13]  M. Piver,et al.  Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy. , 1992, Gynecologic oncology.

[14]  D. Cruickshank,et al.  Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer , 1992, The Lancet.

[15]  R. Ozols,et al.  Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Lynch,et al.  Hereditary ovarian carcinoma. , 1992, Hematology/oncology clinics of North America.

[17]  F. Ognibene,et al.  Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Rubin,et al.  Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. , 1992, Gynecologic oncology.

[19]  G. Demetri,et al.  Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. , 1992, Blood.

[20]  M. Dudzinski,et al.  Endometrioid carcinoma of the ovary presenting with an enlarged inguinal lymph node without evidence of abdominal carcinomatosis. , 1992, Gynecologic oncology.

[21]  K. Swenerton,et al.  Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Alberts,et al.  Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Steinberg,et al.  Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  X. Matías-Guiu,et al.  Ovarian carcinoma preceded by cerebral metastasis: review of the literature. , 1992, Gynecologic oncology.

[25]  R. Bast,et al.  Malignant transformation of ovarian epithelium. , 1992, Journal of the National Cancer Institute.

[26]  J. Berek,et al.  Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon. , 1992, Gynecologic oncology.

[27]  P. Langenberg,et al.  Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Christian,et al.  Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  N. Alexander,et al.  Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? , 1992, American journal of obstetrics and gynecology.

[30]  D. Longo,et al.  Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  T. Bourne,et al.  Ultrasound screening for familial ovarian cancer , 1991, Gynecologic oncology.

[32]  R. Makuch,et al.  Early detection of ovarian cancer: preliminary results of the Yale Early Detection Program. , 1991, The Yale journal of biology and medicine.

[33]  S. Rubin,et al.  Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  L. Delclos,et al.  Twice-daily, split-course abdominopelvic radiation therapy after chemotherapy and positive second-look laparotomy for epithelial ovarian carcinoma. , 1991, International journal of radiation oncology, biology, physics.

[35]  V. Beral,et al.  Pooled analysis of 3 european case‐control studies: I. Reproductive factors and risk of epithelial ovarian cancer , 1991, International journal of cancer.

[36]  G. Lenoir,et al.  Familial breast-ovarian cancer locus on chromosome 17q12-q23 , 1991, The Lancet.

[37]  E. Yordan,et al.  Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Gilks,et al.  Mucinous Tumors of the Appendix Associated With Mucinous Tumors of the Ovary and Pseudomyxoma Peritonei: A Clinicopathological Analysis of 22 Cases Supporting an Origin in the Appendix , 1991, The American journal of surgical pathology.

[39]  S. Howell,et al.  A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Bast,et al.  Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor , 1991, American journal of obstetrics and gynecology.

[41]  S. Rubin,et al.  Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Cannistra.  Why should the clonogenic cell assay be prognostically important in ovarian cancer? , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  H. Stettner,et al.  Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer , 1991, Gynecologic oncology.

[44]  D. Snook,et al.  Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Arnold,et al.  Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. , 1990, The New England journal of medicine.

[46]  John D. Roberts,et al.  Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. , 1990, Cancer Research.

[47]  R. Bast,et al.  High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. , 1990, Gynecologic oncology.

[48]  H. Hansen,et al.  Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  B. Leyland-Jones,et al.  Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[51]  M. Rosenblum,et al.  Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. , 1990 .

[52]  S. Ellenberg,et al.  Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials , 1990, The New England journal of medicine.

[53]  J. Bergerat,et al.  High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France. , 1990, Bone marrow transplantation.

[54]  J. Hainsworth,et al.  High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Elizabeth A. Thompson,et al.  Transvaginal sonography as a screening method for ovarian cancer a report of the first 1000 cases screened , 1990, Cancer.

[56]  G. Sutton,et al.  Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  I. Jansson,et al.  Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: criteria to be used for ultrasound evaluation. , 1989, Gynecologic oncology.

[58]  H. Hansen,et al.  High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  A. Pileri,et al.  GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION , 1989, The Lancet.

[60]  J. Dauplat,et al.  High-dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second-look operation. , 1989, Gynecologic oncology.

[61]  P. Saigo,et al.  Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  P. Saigo,et al.  Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. , 1989, Gynecologic oncology.

[63]  W. Koroshetz,et al.  Case 34-1989 , 1989 .

[64]  D. Ettinger,et al.  Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. , 1989 .

[65]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[66]  C. Begg,et al.  A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  R. Ozols,et al.  Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. , 1989, Journal of the National Cancer Institute.

[68]  J. Berek,et al.  Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  N. Mulder,et al.  High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer. , 1989, European journal of cancer & clinical oncology.

[70]  M. Piver,et al.  Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  W. Thompson,et al.  Familial ovarian cancer: a population-based case-control study. , 1988, American journal of epidemiology.

[72]  A. Martinez,et al.  Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  R. Bast,et al.  Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. , 1988, American journal of obstetrics and gynecology.

[74]  Y. Tomoda,et al.  Preservation of ovarian function and reproductive ability in patients with malignant ovarian tumors. , 1988, Gynecologic oncology.

[75]  M. Piver,et al.  The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  Z. Fuks,et al.  Chemotherapeutic and surgical induction of pathological complete remission and whole abdominal irradiation for consolidation does not enhance the cure of stage III ovarian carcinoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Isabel Stabile,et al.  MULTIMODAL APPROACH TO SCREENING FOR OVARIAN CANCER , 1988, The Lancet.

[78]  J. Hainsworth,et al.  Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. , 1988, Annals of internal medicine.

[79]  G. Sutton,et al.  A comparison of findings at second-look laparotomy with preoperative computed tomography in patients with ovarian cancer. , 1988, Gynecologic oncology.

[80]  S. Howell,et al.  Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  J. Neijt,et al.  Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  K. Anderson,et al.  Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. , 1987, The New England journal of medicine.

[83]  J. Armitage,et al.  High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. , 1987, The New England journal of medicine.

[84]  W. Hryniuk,et al.  Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  Y. Ostchega,et al.  High-dose carboplatin in refractory ovarian cancer patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  R. Bast,et al.  CA 125 for the monitoring of ovarian carcinoma during primary therapy , 1987, Obstetrics and gynecology.

[87]  Y. Ostchega,et al.  Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  R. S. Padilla,et al.  Ovarian adenocarcinoma presenting with the sign of Leser-Trélat. , 1986, Gynecologic oncology.

[89]  J. Blasko,et al.  Salvage therapy with whole‐abdominal irradiation in patients with advanced carcinoma of the ovary previously treated by combination chemotherapy , 1986, Cancer.

[90]  J. Niloff,et al.  The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer , 1986, American journal of obstetrics and gynecology.

[91]  E. Yordan,et al.  A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study , 1986, Cancer.

[92]  R. Bast,et al.  CA 125 serum levels correlated with second-look operations among ovarian cancer patients. , 1986, Obstetrics and gynecology.

[93]  M. Quinn,et al.  Phase II trial of VP-16-213 in advanced ovarian carcinoma. , 1985, Gynecologic oncology.

[94]  R. Bast,et al.  Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. , 1985, Gynecologic oncology.

[95]  R. Bast,et al.  Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. , 1985, European journal of obstetrics, gynecology, and reproductive biology.

[96]  W. Grosh,et al.  Abdominopelvic Computed Tomography: Evaluation in Patients Undergoing Second‐Look Laparotomy for Ovarian Carcinoma , 1985, Obstetrics and gynecology.

[97]  M. Winker,et al.  Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. , 1985, Cancer research.

[98]  R. Bast,et al.  Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. , 1985, American journal of obstetrics and gynecology.

[99]  N. Sneige,et al.  Microscopic disease at second‐look laparotomy in advanced ovarian cancer , 1985, Cancer.

[100]  E. Unger,et al.  Synchronous carcinomas of the uterine corpus and ovary. , 1984, Gynecologic oncology.

[101]  N. Hacker,et al.  Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status. , 1984, Obstetrics and gynecology.

[102]  J. Smyth,et al.  Paraneoplastic hypercalcaemia in ovarian carcinoma. , 1984, British medical journal.

[103]  N. Mulder,et al.  Effective high-dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer. , 1984, Gynecologic oncology.

[104]  B. Edwards,et al.  Staging laparotomy in early ovarian cancer. , 1983, JAMA.

[105]  H. Brashear,et al.  Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma , 1983, Annals of neurology.

[106]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.

[107]  R. Elashoff,et al.  Primary Cytoreductive Surgery for Epithelial Ovarian Cancer , 1983, Obstetrics and gynecology.

[108]  R. Elashoff,et al.  Survival of Patients Following Secondary Cytoreductive Surgery in Ovarian Cancer , 1983, Obstetrics and gynecology.

[109]  W. R. Hart,et al.  Krukenberg tumors of the ovary. A clinicopathologic analysis of 27 cases , 1982, Cancer.

[110]  V. Garwood,et al.  Palmar fasciitis and polyarthritis associated with ovarian carcinoma. , 1982, Annals of internal medicine.

[111]  R. Bast,et al.  Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.

[112]  J. Wharton,et al.  Surgery for common epithelial tumors of the ovary , 1981, Cancer.

[113]  P. Schwartz,et al.  Second-look operations in ovarian cancer. , 1980, American journal of obstetrics and gynecology.

[114]  P. Skarbanek.  Letter: Body-temperature and myasthenia. , 1974, Lancet.